Compare AstraZeneca plc (AZN) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Global X Autonomous & Electric Vehicles — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while Global X Autonomous & Electric Vehicles trades at $35.85. The key difference: AstraZeneca plc pays a 2.01% dividend while Global X Autonomous & Electric Vehicles pays none, and Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | DRIV | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $42.53 |
52-Week Low | $147.06 | $25.23 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
DRIV trades at $35.92, up 0.98% on the day, with a bullish technical signal supported by moving averages and ADX indicators. The stock shows strong momentum, though the short-term RSI suggests overbought conditions. Recent news highlights global EV sales growth and China's aggressive expansion, benefiting the sector. A dividend of $0.07 is scheduled for July 2026, adding income potential.
Outlook remains positive due to sector tailwinds from rising EV adoption and fuel price pressures. Key risks include competitive threats from Chinese automakers and regulatory delays. Analysts are generally bullish, but investors should monitor valuation gaps and execution risks amid rapid industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
